

**Senate Community Affairs Committee**

ANSWERS TO ESTIMATES QUESTIONS ON NOTICE

HEALTH PORTFOLIO

**Supplementary Budget Estimates 2015 - 2016, 21 October 2015**

**Ref No:** SQ15-000695

**OUTCOME:** 2 - Access to Pharmaceutical Services

**Topic:** Transgender People – Access to Medical Treatment

**Type of Question:** Hansard Page 88, 21 October 2015

**Senator:** Rice, Janet

**Question:**

- a) Have you not received any application or any proposal before now (in relation to stage 1 treatment, puberty blockers, gonadotrophin-releasing analogues)?
- b) Has there been any consideration or any determination of them so far (basically it is the puberty blocker, the gonadotrophin- releasing hormone analogues)?

**Answer:**

a) and b)

As at 1 November 2015, the Department of Health has not received any submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) requesting Pharmaceutical Benefits Scheme listing for a gonadotrophin-releasing hormone analogue (e.g. leuprorelin) for the purpose of blocking puberty in transgender persons.